Skip to content
Golden Arena Zone

The Zimbabwean Government Declines ‘Unbalanced’ US Healthcare Assistance Package Over Information Apprehensions

Medical aid image
The offered US financial assistance would have supported programmes for treating and preventing HIV/Aids, tuberculosis, and malaria.

Zimbabwe has declined a significant US healthcare agreement worth 367 million US dollars (272 million pounds) over five years due to the United States' request for sensitive biological samples.

This rejection was revealed after a government memo from December was disclosed, which showed President Emmerson Mnangagwa felt the agreement was "skewed".

A government representative has since clarified that the US was demanding access to biological samples for research and commercial purposes but was unwilling to share the benefits from future vaccines.

"We must now begin the challenging and unfortunate process of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.

The US Embassy noted the United States had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.

A doctors' association in Zimbabwe has urged further dialogue to reach a deal acceptable to both sides so the country's critical HIV treatment initiative can be sustained.

Broader Context

Zimbabwe's decision follows a similar case in Kenya, where a court blocked a similar health funding agreement after concerns were filed about the security of Kenyans' health data.

Since returning to the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).

The agency had administered assistance for the US government, but Trump stated its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to enhance transparency and responsibility.

According to reports, Sixteen African countries have so far signed these new agreements, constituting more than $18.3bn in new funding.

Specifics of the Declined Deal

The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.

"We believe this collaboration could have provided extraordinary advantages for Zimbabwean communities, particularly the 1.2 million currently receiving antiretroviral therapy through American-funded initiatives," the Ambassador said.

However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".

"The proposal required Zimbabwe to share its genetic material and health information over an extended period, without any equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that might result from that shared data," he stated.

"Effectively, our country would provide the raw materials for medical research with no assurance that the final treatments would be available to our people if a future disease outbreak arise."

National Interest and Global Health

Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining systems previously set up via the international health agency.

Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to manage potential global health emergencies.

"This system is intended to ensure that when a country provides its data, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to create them."

The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.

"We welcome continued discussions with our US partners on how future collaboration might be structured in a way that honours the sovereignty and interests of both nations."

Medical Community Reaction

Medical experts expressed it recognised the official position, but suggested that talks need to persist considering a large portion of the nation's HIV programmes relied on international support.

"If technical issues exist, including those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," it added.

The halted deal highlights the complex challenges between accepting vital international aid and safeguarding a country's data in an ever more data-driven world.

By

Melissa Clayton

Eva is een ervaren content creator en evenementenexpert met een passie voor het delen van de mooiste ervaringen.

Golden Arena Zone

Type to search articles.